Ovarian Cancer

Although one patient with recurrent ovarian cancer achieved complete response, the first trial of abiraterone conducted in ovarian cancer was halted early due to low response, according to results from the CORAL phase 2 trial.

The antibody drug conjugate XMT-1536 could change the treatment paradigm for both non-small cell lung cancer (NSCLC) and ovarian cancer, according to Donald Bergstrom, MD, PhD.

Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the clinical activity and efficacy of rucaparib in patients with high-grade ovarian carcinoma and a BRCA mutation during an interview at the 2016 ESMO Congress.

Findings of a recent preliminary clinical trial showed one-fourth of patients with heavily pretreated advanced ovarian cancer achieved objective responses with novel antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7).

The majority of heavily pretreated patients with high-grade ovarian cancer (HGOV) and germline or somatic <em>BRCA</em> mutations showed a durable response to rucaparib, according to findings from an analysis of two phase II trials.

Maintenance therapy with the PARP1/2 inhibitor niraparib reduced the risk of progression or death by 73% compared with placebo for patients with germline <em>BRCA</em>-positive platinum-sensitive, recurrent ovarian cancer, according to findings from the phase III NOVA trial.

Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses when to perform a prophylactic bilateral oophorectomy on a patient who does not have ovarian cancer, but has a known BRCA mutation.

Niraparib has been granted a fast track designation by the FDA as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer, the company developing the PARP inhibitor, Tesaro, has announced.

Don Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses the future of XMT-1536 in the treatment of ovarian cancer and non-small cell lung cancer (NSCLC).

Undergoing surgery to prevent ovarian cancer should depend on familial history, as well as age, according to Maurie Markman, MD.

Leslie M. Randall, MD, associate professor of Gynecology/Oncology, University of California Irvine, discusses the use of olaparib as maintenance therapy in the treatment of patients with ovarian cancer.

Priority review has been granted by the FDA for a new drug application (NDA) for rucaparib as a treatment for patients with&nbsp;<em>BRCA</em>-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy, according to Clovis, the manufacturer of the PARP inhibitor.

Results of a phase I trial demonstrate that the combination of niraparib and bevacizumab can be safely administered to patients with platinum-sensitive relapsed ovarian cancer.

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, discusses the benefits and risks of performing a bilateral salpingo-oophorectomy as a treatment for patients with ovarian cancer.

Allison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine, discusses two ongoing trials utilizing multi-gene panels to uncover previously undetected risks in patients with breast and ovarian cancer.

Multigene panel testing may uncover new risks in breast cancer and ovarian cancer.

BRCA mutation testing in patients with ovarian cancer could mean a world of difference in treatment, says Robert Coleman, MD.

Early identification of BRCA mutations can significantly help inform future treatment choices for patients with ovarian cancer, says Leslie Randall, MD.

A novel dual-pathway inhibitor of tumor angiogenesis passed a preliminary clinical test, demonstrating manageable toxicity and biomarker evidence of engagement with the drug's targets, as reported at the 2016 ASCO Annual Meeting in Chicago.

Robert L. Coleman, MD, discusses the importance of early BRCA testing for patients with ovarian cancer.

The largest-ever genetic analysis of ovarian cancer patients yielded a short list of 11 suspect germline genetic mutations that may be associated with an increased risk for developing ovarian cancer, according to an oral presentation at the 2016 ASCO Annual Meeting in Chicago.

Loss of genomic heterozygosity is a marker for the efficacy of rucaparib even in patients without BRCA 1 and 2 mutations, according to a poster presented Monday at the 2016 ASCO Annual Meeting.

It is feasible to administer the PARP inhibitor niraparib in combination with bevacizumab to patients with platinum-sensitive relapsed ovarian cancer with manageable toxicities. The results of a phase I study (NCT02354131) in 12 patients were presented during a poster session at the 2016 ASCO Annual Meeting.

Napabucasin (BBI-608, BB608) is a first-in-class cancer "stemness" inhibitor that targets the STAT3 pathway, has acceptable toxicity, and shows some antitumor activity in combination with paclitaxel in platinum-resistant ovarian cancer. Results of an early phase trial were presented at a poster session at the 2016 ASCO Annual Meeting.

Avelumab (MSB0010718C), a fully human anti-PD-L1 (programmed death-1 receptor ligand) IgG1 antibody, showed activity in patients with heavily pretreated recurrent or refractory ovarian cancer with acceptable toxicity in the phase Ib JAVELIN Solid Tumor trial.